Enliven Therapeutics Inc. (NASDAQ: ELVN) announced it will present updated Phase 1 clinical trial data for ELVN-001 in chronic myeloid ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE